Conference Coverage

CMSC MRI guidelines evolve into international consensus protocol


 

From CMSC 2020

Proposed updates to guidelines for magnetic resonance imaging in patients with multiple sclerosis (MS) are in the works to make the Consortium of Multiple Sclerosis Centers protocol and other international guidelines more similar, with the hope that internationally accepted consensus guidelines will improve lagging conformity with the recommendations.

“We’ve always envisioned the guidelines as being international, but now we have harmony with the groups, so this is truly a global protocol,” Anthony Traboulsee, MD, a professor of neurology and director of the MS clinic and neuromyelitis optica clinic at the University of British Columbia in Vancouver, said in presenting the proposed updates during the virtual meeting of the CMSC.

The updates reflect the input of an international expert panel convened by the CMSC in October 2019, made up of neurologists, radiologists, magnetic resonance technologists, and imaging scientists with expertise in MS. Attendees represented groups including the European-based Magnetic Resonance Imaging in MS (MAGNIMS), North American Imaging in Multiple Sclerosis Cooperative, National MS Society, Multiple Sclerosis Association of America, MRI manufacturers, and commercial image analysis.

Standardizing scans

While the mission was to review and update the current guidelines, an important overriding objective was to boost universal acceptance and improve the utilization of the protocol, which research shows is surprisingly low. According to one poster presented at the meeting, a real-world MRI dataset of 1,233 sessions showed only 8% satisfied criteria for the T1 sequence outlined in the 2018 guidelines, and only 7% satisfied criteria for the T2 sequence. “In a real-world MRI dataset of patients with MS, the conformance to the CMSC brain MRI guidelines was extremely low,” concluded the authors, who were with Icometrix, in Chicago and Belgium.

David Li, MD, also of the University of British Columbia and cochair of the MRI guideline committee, said the nonconformity has important implications. “Nonstandardized scans, with inconsistent slice thickness and gaps, nonstandardized slice acquisition (not in the subcallosal plane), and incomplete brain coverage, all contribute to scans that are difficult to compare,” he said. Those factors, “allow for assessment of new lesions and lesion activity that are invaluable for diagnosis as well as determining the effectiveness of therapy or the need for initiating/changing therapy.”

Dr. Traboulsee said the lack of adherence to guidelines may simply have to do with a mistaken perception of complexity. “Part of the challenge is MRI centers don’t realize how easy it is to implement these guidelines,” he said in presenting the proposed updates.

Dr. Traboulsee noted that the CMSC has been working with manufacturers to try to incorporate the protocol into the scanners “so that it’s just a button to press” for the MRI. “I think that will get us over a major hurdle of adaptation,” Dr. Traboulsee said. “Most radiologists said once they started using it they were really happy with it. They found they were using it beyond MS for other basic neurologic imaging, so just raising awareness and making things more of a one-step process for individuals to use will be helpful,” he said.

Pages

Recommended Reading

Newest oral DMTs haven’t yet made a big impact in the MS world
ICYMI Multiple Sclerosis
Herpes zoster infection with MS treatment higher in women?
ICYMI Multiple Sclerosis
Is hematopoietic stem cell transplant linked to neurotoxicity in MS?
ICYMI Multiple Sclerosis
MS: Effects of vitamin D3 supplementation on inflammatory cytokines
ICYMI Multiple Sclerosis
Pro-inflammatory diet during adolescence is a risk factor for MS onset
ICYMI Multiple Sclerosis
Long-term effectiveness of induction vs escalation therapy in relapsing-remitting MS
ICYMI Multiple Sclerosis
Function in MS may vary significantly within EDSS scores
ICYMI Multiple Sclerosis
Cannabis misconceptions still common among MS clinicians
ICYMI Multiple Sclerosis
FDA approves Uplizna for treatment of anti-AQP4 antibody–positive NMOSD
ICYMI Multiple Sclerosis
Relapsing, progressive MS classifications should be abandoned
ICYMI Multiple Sclerosis